The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Inhibition of Vps34 reprograms cold into hot inflamed tumors and improves anti–PD-1/PD-L1 immunotherapy
Open accessAbstract
Targeting Vps34 makes melanoma and CRC eligible to anti–PD-1/PD-L1 blockade.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In a mouse CRC model, the autophagy inhibitors, such as SB02024 and SAR405, increased NK and T cell infiltration in TME and reversed resistance to anti-PD-1 or anti-PD-L1 [47].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [47]
The cited source says what the claim attributes to it.
In the citing paper
“Supporting this finding, lysosomotropic agents or small molecules targeting the PtdIns3K PIK3C3/VSP34 have been efficiently combined with therapeutic regimens that promote the activation of the immune system against cancer cells (Janji et al, 2020; Noman et al, 2020).”
From Autophagy in major human diseases (2021) · cites this paper as Noman et al, 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 2×
“This statement is supported by clinical data showing that the presence of preexisting T cells close to the invasive tumor margin is a key determinant to achieving a long-lasting response to anti–PD-1 therapy in melanoma (4).”
Autophagy: Renovation of Cells and Tissues
Mizushima, N., & Komatsu, M. (2011) · Cell · doi:10.1016/j.cell.2011.10.026 · Cited by 6,418
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733 · cited 5×
“INTRODUCTION Immune checkpoint inhibitors (ICIs), exemplified by antibodies targeting programmed death 1 (PD-1) or programmed death ligand 1 (PD-L1), are groundbreaking treatment for many cancers, including melanoma (1).”
InfluentialChemokines in the cancer microenvironment and their relevance in cancer immunotherapy
Nagarsheth, N., Wicha, M. S., & Zou, W. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.49 · Cited by 2,206 · cited 1×
“CCL5, CXCL10, and IFN are all known to promote recruitment of cytotoxic T cells into the TME (18), and this is likely the explanation for why we observed enhanced recruitment of NK, CD8+ T, and CD4+ T effector cells into the tumor bed following Vps34 inhibition.”
Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131916 · Cited by 2,166
Self-citationCurran, M. A., Montalvo, W., Yagita, H., & Allison, J. P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915174107 · Cited by 1,874 · cited 1×
“We used melanoma B16F10, previously described as immune hot tumors but not responding to anti–PD-L1/PD-1 (21), and CRC CT26, reported as immune cold tumors and partially responding to anti–PD-L1/PD-1 (22).”
Pancreatic cancers require autophagy for tumor growth
Yang, S., Wang, X., Contino, G., Liesa, M., Sahin, E., Ying, H., Bause, A., Li, Y., Stommel, J. M., Dell'Antonio, G., et al. (2011) · Genes & Development · doi:10.1101/gad.2016111 · Cited by 1,498 · cited 1×
“While the impact of blocking autophagy on the inhibition of tumor growth has been well documented by several studies ( 7 , 8 , 14 , 23 – 26 ), the effect of targeting autophagy on the immune landscape of tumors is still only partially defined.”
Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment
Harlin, H., Meng, Y., Peterson, A. C., Zha, Y., Tretiakova, M., Slingluff, C., McKee, M., & Gajewski, T. F. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2281 · Cited by 1,121
Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
Sistigu, A., Yamazaki, T., Vacchelli, E., Chaba, K., Enot, D. P., Adam, J., Vitale, I., Goubar, A., Baracco, E. E., Remédios, C., et al. (2014) · Nature Medicine · doi:10.1038/nm.3708 · Cited by 1,042 · cited 1×
“In this regard, it is tempting to speculate that type I IFN signature could be responsible for triggering the release of more CCL5 and CXCL10 in the TME, as previously reported (37), to attract more NK and CD8+ T cells into the tumor bed.”
Hegde, P. S., Karanikas, V., & Evers, S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1507 · Cited by 1,000 · cited 1×
“The immune phenotyping of tumors combined with the cytokine network results reported in this study strongly predicts that the immune-supportive characteristic of Vps34itreated TME relies on the establishment of an inflamed TME supported by the presence of tumor-infiltrating lymphocytes, high levels of IFN-producing C…”
Cited by
Autophagy in major human diseases
Klionsky, D. J., Petroni, G., Amaravadi, R. K., Baehrecke, E. H., Ballabio, A., Boya, P., Bravo‐San Pedro, J. M., Cadwell, K., Cecconi, F., Choi, A. M. K., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2021108863 · Cited by 1,585
Self-citationAutophagy and autophagy-related pathways in cancer
Debnath, J., Gammoh, N., & Ryan, K. M. (2023) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00585-z · Cited by 1,403
Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy
Gao, W., Wang, X., Zhou, Y., Wang, X., & Yu, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01046-3 · Cited by 1,042
“Vps34 inhibitor SB02024 or SAR405 results in elevated levels of CCL5, IFNγ, and other chemokines in TME, causing high levels of NK cells and T cells infiltration in myeloma and colorectal cancer models.(411) Furthermore, in an osteosarcoma model, tumor immunogenicity promoted by photodynamic therapy can be counteracte…”
BackgroundSelf-citationCold and hot tumors: from molecular mechanisms to targeted therapy
Wu, B., Zhang, B., Li, B., Wu, H., & Jiang, M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01979-x · Cited by 682
Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer
Wu, F., Yang, J., Liu, J., Wang, Y., Mu, J., Zeng, Q., Deng, S., & Zhou, H. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00641-0 · Cited by 773
Turning cold tumors hot: from molecular mechanisms to clinical applications
Zhang, J., Huang, D., Saw, P. E., & Song, E. (2022) · Trends in Immunology · doi:10.1016/j.it.2022.04.010 · Cited by 534
Recent Advances in Hyperthermia Therapy‐Based Synergistic Immunotherapy
Chang, M., Hou, Z., Wang, M., Li, C., & Lin, J. (2021) · Advanced Materials · doi:10.1002/adma.202004788 · Cited by 450
Autophagy in tumour immunity and therapy
Xia, H., Green, D. R., & Zou, W. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00344-2 · Cited by 404
The multifaceted role of autophagy in cancer
Russell, R. C., & Guan, K. (2022) · The EMBO Journal · doi:10.15252/embj.2021110031 · Cited by 222
“Pharmacological inhibition of autophagy using VPS34 inhibitors has been shown to increase inflammation and T-cell infiltration (Noman et al , 2020).”
Targeting autophagy in disease: established and new strategies
Kocak, M., Ezazi Erdi, S., Jorba, G., Maestro, I., Farrés, J., Kirkin, V., Martinez, A., & Pless, O. (2022) · Autophagy · doi:10.1080/15548627.2021.1936359 · Cited by 228
“ULK1-ULK2 complex inhibitors: SBI-0206965 was discovered as a small molecule pyrimidine analog ULK1 kinase inhibitor, with biochemical IC50 of 108 nM for ULK1 kinase activity and 711 nM for ULK2 [164].”
BackgroundInfluentialAutophagy in cancer development, immune evasion, and drug resistance
Niu, X., You, Q., Hou, K., Tian, Y., Wei, P., Zhu, Y., Gao, B., Ashrafizadeh, M., Aref, A. R., Kalbasi, A., et al. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2024.101170 · Cited by 191
Extracellular Vesicles: New Classification and Tumor Immunosuppression
Sheta, M., Taha, E. A., Lu, Y., & Eguchi, T. (2023) · Biology · doi:10.3390/biology12010110 · Cited by 206
“Inhibition of Vps34 reprograms cold into hot, inflamed tumors and improves anti-PD-1/PD-L1 immunotherapy [32].”
BackgroundZhang, S., Zhang, Y., Feng, Y., Wu, J., Hu, Y., Lin, L., Xu, C., Chen, J., Tang, Z., Tian, H., et al. (2022) · Advanced Materials · doi:10.1002/adma.202206851 · Cited by 208
Emerging roles of ATG7 in human health and disease
Collier, J. J., Suomi, F., Oláhová, M., McWilliams, T. G., & Taylor, R. W. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202114824 · Cited by 193
“This was demonstrated recently whereby Vps34 inhibition improved immunotherapy outcomes in preclinical models (Noman et al, 2020).”
BackgroundZheng, S., Wang, W., Shen, L., Yao, Y., Xia, W., & Ni, C. (2024) · Experimental Hematology & Oncology · doi:10.1186/s40164-024-00543-1 · Cited by 163
“Typically, DC maturation signals are released by dying tumor cells and act as cues for potential non-self-substances [116].”
BackgroundZhang, F., Ma, Y., Li, D., Wei, J., Chen, K., Zhang, E., Liu, G., Chu, X., Liu, X., Liu, W., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01600-2 · Cited by 209
“…immune checkpoint therapy is the inability of CD8 + T-cells to infiltrate the TME of the ‘cold tumor’, which is mainly attributed to the physical barrier formed by CAFs-induced remodeling of the ECM, which prevents the infiltration of anti-tumor immune cells and effective drug delivery [264, 265].”
BackgroundDrug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
Beyond PI3Ks: targeting phosphoinositide kinases in disease
Burke, J. E., Triscott, J., Emerling, B. M., & Hammond, G. R. V. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00582-5 · Cited by 156
Autophagy Regulates Stress Responses, Metabolism, and Anticancer Immunity
White, E. P., Lattime, E. C., & Guo, J. Y. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.05.003 · Cited by 150
Recent advances in targeting autophagy in cancer
Jain, V., Singh, M. P., & Amaravadi, R. K. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.02.003 · Cited by 151
Self-citationExploring the Emerging Role of the Gut Microbiota and Tumor Microenvironment in Cancer Immunotherapy
Qiu, Q., Lin, Y., Ma, Y., Li, X., Liang, J. B., Chen, Z., Liu, K., Huang, Y., Luo, H., Huang, R., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.612202 · Cited by 151
Recent Advances and Challenges in Cancer Immunotherapy
Peterson, C. M., Denlinger, N., & Yang, Y. (2022) · Cancers · doi:10.3390/cancers14163972 · Cited by 146
“Other autophagy-inhibiting targets may inhibit tumor growth in melanoma and CRC while enhancing ICI efficacy [141].”
BackgroundDocking-Based Virtual Screening Using PyRx Tool: Autophagy Target Vps34 as a Case Study
Kondapuram, S. K., Sarvagalla, S., & Coumar, M. S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822312-3.00019-9 · Cited by 136
Autophagy in health and disease: From molecular mechanisms to therapeutic target
Lu, G. X., Wang, Y., Shi, Y. P., Zhang, Z., Huang, C., He, W., Wang, C., & Shen, H. (2022) · MedComm · doi:10.1002/mco2.150 · Cited by 147
Lequeux, A., Noman, M. Z., Xiao, M., Van Moer, K., Hasmim, M., Benoit, A., Bosseler, M., Viry, E., Arakelian, T., Berchem, G., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01846-x · Cited by 129
“4C) which reactivate CD8 T cells in B16-F10 melanoma [9, 27].”
BackgroundSelf-citationA perspective on the role of autophagy in cancer
Ariosa, A., Lahiri, V., Lei, Y., Yang, Y., Yin, Z., Zhang, Z., & Klionsky, D. J. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166262 · Cited by 119
Autophagy protects tumors from T cell–mediated cytotoxicity via inhibition of TNFα-induced apoptosis
Young, T. M., Reyes, C., Pasnikowski, E. M., Castanaro, C., Wong, C. F., Decker, C. E., Chiu, J., Song, H., Wei, Y., Bai, Y., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abb9561 · Cited by 118
The role of CXCR3 and its ligands in cancer
Wang, X., Zhang, Y., Wang, S., Ni, H., Zhao, P., Chen, G., Xu, B., & Yuan, L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1022688 · Cited by 136
“Studies have shown that the CXCR3-CXCL9/10 axis is crucial in combined immunotherapy (53, 56, 57).”
BackgroundLi, H., Wen, X., Ren, Y., Fan, Z., Zhang, J., He, G., & Fu, L. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02072-1 · Cited by 125
“Beyond BC, 83 showed promise in synergizing with PD-L1/PD-1 therapies, offering potential treatment avenues for melanoma and CRC [351, 354].”
BackgroundTurning cold tumors into hot tumors to ignite immunotherapy
Liu, Y., Wang, Y., Wang, S., Li, J., He, W. A., Fan, X.-J., & Wan, X. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02477-6 · Cited by 133
Small molecule probes for targeting autophagy
Whitmarsh‐Everiss, T., & Laraia, L. (2021) · Nature Chemical Biology · doi:10.1038/s41589-021-00768-9 · Cited by 114
Lee, C., Bae, J.-H., Choe, E., Park, J., Park, S., Cho, H. J., Song, B., & Baek, M. (2022) · Theranostics · doi:10.7150/thno.68864 · Cited by 112
“In contrast, the efficacy of ICB is increased through the conversion from a cold tumor to a hot tumor by increasing PD-L1 [39-42].”
BackgroundLi, J., Fang, Y., Zhang, Y., Wang, H., Yang, Z., & Ding, D. (2021) · Advanced Materials · doi:10.1002/adma.202008518 · Cited by 110
Pparg signaling controls bladder cancer subtype and immune exclusion
Tate, T., Xiang, T., Wobker, S. E., Zhou, M., Chen, X., Kim, H.-W., Batourina, E., Lin, C., Kim, W. Y., Lü, C., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26421-6 · Cited by 116
Yang, Z., Yan, G., Zheng, L., Gu, W., Liu, F., Chen, W., Cui, X., Wang, Y., Yang, Y., Chen, X., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1938890 · Cited by 123
Qiao, Y., Choi, J. E., Tien, J. C.-Y., Simko, S. A., Rajendiran, T. M., Vo, J. N., Delekta, A. D., Wang, L., Xiao, L., Hodge, N., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00237-1 · Cited by 114
Ji, S., Li, J., Duan, X., Zhang, J., Zhang, Y., Song, M., Li, S., Chen, H., & Ding, D. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202110512 · Cited by 104
Novel antitumor therapeutic strategy using CD4+ T cell-derived extracellular vesicles
Shin, S., Jung, I., Jung, D., Kim, C. S. K., Kang, S., Ryu, S., Choi, S.-J., Noh, S., Jeong, J., Lee, B. Y., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121765 · Cited by 106
Li, X., Lu, M., Yuan, M., Ye, J., Zhang, W., Xu, L., Wu, X., Hui, B., Yang, Y., Wei, B., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2118210 · Cited by 105
“Furthermore, many other studies have suggested that intratumoural CXCL10 signaling is positively correlated with the efficacy of immune checkpoint blockade (ICB) treatment.(11,14,15) Consistent with our former discovery, the reported mechanism of these articles is related to more CXCR3 T cells infiltrating the TME, ma…”
BackgroundJung, D., Shin, S., Kang, S., Jung, I., Ryu, S., Noh, S., Choi, S., Jeong, J., Lee, B. Y., Kim, K., et al. (2022) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12287 · Cited by 100
“…low response rate of patients with melanoma to chemotherapy (Legha et al., 1996; Pectasides et al., 1989) and immunotherapy (Cascio et al., 2021; Noman et al., 2020; Chen et al., 2018), we assessed whether IL2-sEVs could enhance the therapeutic efficacy of known anti-cancer drugs, including…”
BackgroundInfluentialRaudenská, M., Balvan, J., & Masařík, M. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01423-6 · Cited by 99
“Using SAR405 decreased the tumour growth and improved mouse survival in multiple tumour models by inducing tumour infiltration of NK, CD8+, and CD4+ T effector cells [96] and repressed viability of liver cancer stem cells [97].”
BackgroundWang, Y., Ding, Y., Yao, D., Dong, H., Ji, C., Wu, J., Hu, Y., & Yuan, A. (2021) · Small · doi:10.1002/smll.202006231 · Cited by 93
Cancer Immunotherapies: From Efficacy to Resistance Mechanisms – Not Only Checkpoint Matters
Wang, S., Xie, K., & Liu, T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.690112 · Cited by 103
Guan, L., Wu, B., Li, T., Beer, L. A., Sharma, G., Li, M., Lee, C. N., Liu, S., Yang, C., Huang, L., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31713-6 · Cited by 89
“VHS FYVE UIM PSAP CB 1-1 39 15 5-2 21 25 7-2 77 34 8-3 51 70 4-7 77 CC 46 9-5 53 i (1-777) 100 70”
Self-citationCheung, P. F., Yang, J., Fang, R., Borgers, A., Krengel, K., Stoffel, A., Althoff, K., Yip, C. W., Siu, E. H.-L., Ng, L. W. C., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27088-9 · Cited by 87
Ashrafizadeh, M., Dai, J., Torabian, P., Nabavi, N., Aref, A. R., Aljabali, A. A. A., Tambuwala, M. M., & Zhu, M. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05236-w · Cited by 95
“Furthermore, miRNAs can be sponged by lncRNAs and cir-cRNAs [ 128, 129]. miRNAs demonstrate dysregulation in tumorigenesis and are biomarkers.”
BackgroundAutophagy in the cancer-immunity dialogue
Yamazaki, T., Pedro, J. M. B., Galluzzi, L., Kroemer, G., & Pietrocola, F. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.12.003 · Cited by 86
Anti-PD-1/PD-L1 therapy for colorectal cancer: Clinical implications and future considerations
Chen, X., Chen, L., Peng, X., Deng, L., Wang, Y., Li, J.-J., Guo, D., & Niu, X. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101851 · Cited by 86
“This method uses the patient ’ s immune system to improve the chances of survival or slow disease progression [1 – 3].”
MethodBustos, S. O., Antunes, F., Rangel, M. C., & Chammas, R. J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.606436 · Cited by 82
Lin, Z., Xiong, Y., Meng, W., Hu, Y., Chen, L., Chen, L., Xue, H., Panayi, A. C., Zhou, W., Sun, Y. T., et al. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.10.042 · Cited by 75
Autophagy in cancer cell remodeling and quality control
Hernandez, G. A., & Perera, R. M. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.03.023 · Cited by 77
Cai, Z., Chen, J., Yu, Z.-Z., Li, H., Liu, Z., Deng, D., Liu, J., Chen, C., Zhang, C., Ou, Z., et al. (2023) · Advanced Science · doi:10.1002/advs.202207155 · Cited by 86
Nanotechnology Reprogramming Metabolism for Enhanced Tumor Immunotherapy
Zhou, Y., Yuan, J. T., Xu, K., Li, S., & Liu, Y. (2024) · ACS Nano · doi:10.1021/acsnano.3c11260 · Cited by 78
Mukhopadhyay, S., Mahapatra, K. K., Praharaj, P. P., Patil, S., & Bhutia, S. K. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.09.003 · Cited by 72
Mechanisms of CD8+ T cell exclusion and dysfunction in cancer resistance to anti-PD-(L)1
Mortezaee, K., & Majidpoor, J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114824 · Cited by 72
Carnosine regulation of intracellular pH homeostasis promotes lysosome-dependent tumor immunoevasion
Yan, R., Zhang, P., Shen, S., Zeng, Y., Wang, T., Chen, Z., Ma, W., Feng, J., Suo, C., Zhang, T., et al. (2024) · Nature Immunology · doi:10.1038/s41590-023-01719-3 · Cited by 66
Truong, T., Webber, K. G. I., Johnston, S. M., Boekweg, H., Lindgren, C. M., Liang, Y., Nydegger, A., Xie, X., Tsang, T., Jayatunge, D., et al. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202303415 · Cited by 68
Targeting Autophagy to Treat Cancer: Challenges and Opportunities
Lim, J., & Murthy, A. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.590344 · Cited by 63
Autophagy in Cancer Immunotherapy
Lei, Y., Zhang, E., Bai, L., & Li, Y. (2022) · Cells · doi:10.3390/cells11192996 · Cited by 65
Inhibition of autophagy and MEK promotes ferroptosis in Lkb1-deficient Kras-driven lung tumors
Bhatt, V. D., Lan, T., Wang, W., Kong, J., Lopes, E. C., Wang, J., Khayati, K., Raju, A., Rangel, M., Lopez, E., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05592-8 · Cited by 64
The interplay between autophagy and cGAS-STING signaling and its implications for cancer
Schmid, M., Fischer, P., Engl, M., Widder, J., Gruber, S., & Slade, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1356369 · Cited by 66
Loss of Rnf31 and Vps4b sensitizes pancreatic cancer to T cell-mediated killing
Frey, N., Tortola, L., Egli, D., Janjuha, S., Rothgangl, T., Marquart, K. F., Ampenberger, F., Köpf, M., & Schwank, G. (2022) · Nature Communications · doi:10.1038/s41467-022-29412-3 · Cited by 59
The Role of Toll-like Receptor Agonists and Their Nanomedicines for Tumor Immunotherapy
Huang, L., Ge, X., Liu, Y., Li, H., & Zhang, Z. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061228 · Cited by 61
Pimentel, J. M., Zhou, J. Y., & Wu, G. S. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217285 · Cited by 56
Shintani, Y., Kimura, T., Funaki, S., Ose, N., Kanou, T., & Fukui, E. (2023) · Cancers · doi:10.3390/cancers15020335 · Cited by 57
“One major reason for cancers failing to respond to anti-PD-1/PD-L immune checkpoint therapy is that CD8+ T cells cannot infiltrate into the tumor [135].”
BackgroundLin, Z., Huang, K., Guo, H., Jia, M., Liu, X., 孙秋芹, Chen, X., Wu, J., Yao, Q., Zhang, P., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114567 · Cited by 61
Oxidative Stress in Cancer Immunotherapy: Molecular Mechanisms and Potential Applications
Liu, R., Peng, L., Zhou, L., Huang, Z., Zhou, C., & Huang, C. (2022) · Antioxidants · doi:10.3390/antiox11050853 · Cited by 52
Targeting the Metabolic Rewiring in Pancreatic Cancer and Its Tumor Microenvironment
Yamamoto, K., Iwadate, D., Kato, H., Nakai, Y., Tateishi, K., & Fujishiro, M. (2022) · Cancers · doi:10.3390/cancers14184351 · Cited by 52
The pleiotropic functions of autophagy in metastasis
Marsh, T., Tolani, B., & Debnath, J. (2021) · Journal of Cell Science · doi:10.1242/jcs.247056 · Cited by 50
CXCL10 Is an Agonist of the CC Family Chemokine Scavenger Receptor ACKR2/D6
Chevigné, A., Janji, B., Meyrath, M., Reynders, N., D’Uonnolo, G., Uchański, T., Xiao, M., Berchem, G., Ollert, M. W., Kwon, Y., et al. (2021) · Cancers · doi:10.3390/cancers13051054 · Cited by 49
“In particular, the interferon gamma-induced chemokine CXCL10, also known as IP-10, reported to sustain tumour growth via autocrine loops [39] and to drive T lymphocytes and NK cells through activation of CXCR3 [37,40,41], is often upregulated in the same manner or simultaneously with CC inflammatory chemokines [42].”
BackgroundSelf-citationJanji, B., Hasmim, M., Parpal, S., Milito, A. D., Berchem, G., & Noman, M. Z. (2020) · Autophagy · doi:10.1080/15548627.2020.1815439 · Cited by 48
“[1] Noman MZ, Parpal S, Moer KV, et al.”
BackgroundSelf-citationTargeting Cytoprotective Autophagy to Enhance Anticancer Therapies
Xiao, M., Benoit, A., Hasmim, M., Duhem, C., Vogin, G., Berchem, G., Noman, M. Z., & Janji, B. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.626309 · Cited by 48
Self-citationChicote, J., Yuste, V. J., Boix, J., & Ribas, J. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.580343 · Cited by 48
Chen, L., Jiang, X., Li, Y., Zhang, Q., Li, Q., Zhang, X., Zhang, M., Yu, Q., & Gao, D. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.108962 · Cited by 50
Autophagy and cancer: Basic mechanisms and inhibitor development
Hama, Y., Ogasawara, Y., & Noda, N. N. (2023) · Cancer Science · doi:10.1111/cas.15803 · Cited by 53
PIK3C3 Inhibition Promotes Sensitivity to Colon Cancer Therapy by Inhibiting Cancer Stem Cells
Kumar, B., Ahmad, R., Sharma, S., Gowrikumar, S., Primeaux, M., Rana, S., Natarajan, A., Oupický, D., Hopkins, C. R., Dhawan, P., et al. (2021) · Cancers · doi:10.3390/cancers13092168 · Cited by 48
“A recent report using yet another PIK3C3/VPS34 inhibitor showed similar anti-cancer effects in treating colon cancer by modulating the immune checkpoint regulators [16].”
BackgroundWang, Y., Gu, W., Wen, W., & Zhang, X. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2021.756094 · Cited by 51
“Tumor-infiltrating immune cells are considered to be a marker of host antitumor immune response and prognostic feature (Noman et al., 2020; and; Väyrynen et al., 2020).”
BackgroundDong, Y. J., Zhu, G., Wang, S.-F., Keon, K. A., Rubinstein, J. L., Zeng, S.-X., Zhang, S., Chen, Q., Fu, J. W., Li, M., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.71041 · Cited by 46
Enhancing Anti-Cancer Therapy with Selective Autophagy Inhibitors by Targeting Protective Autophagy
Lee, M. J., Park, J., Jo, S. B., & Joe, Y. A. (2022) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2022.153 · Cited by 45
“ULK1 initiation complex then recruits class III PI3K nucleation complex composed of BECLIN 1 (human homolog of yeast ATG6), ATG14, type III phosphatidylinositol 3-kinase/vacuolar protein sorting 34 (class III PI3K/VPS34), autophagy and BECLIN 1 regulator-1 (AMBRA1), and UV radiation resistance-associated gene protein…”
BackgroundInfluentialTaraborrelli, L., Şenbabaoğlu, Y., Wang, L., Lim, J., Blake, K., Kljavin, N. M., Gierke, S., Scherl, A., Ziai, J. M., McNamara, E., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41618-7 · Cited by 47
Inhibition of autophagy; an opportunity for the treatment of cancer resistance
Tonkin-Reeves, A., Giuliani, C. M., & Price, J. T. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1177440 · Cited by 45
“More recently, it has been shown to induce inflammation within the tumour and provide an environment for the successful use of immunotherapeutic agents in vivo in melanoma and colorectal cancer models (Noman et al., 2020).”
BackgroundThibault, B., Ramos-Delgado, F., & Guillermet-Guibert, J. (2023) · Cancers · doi:10.3390/cancers15030784 · Cited by 40
“Indeed, Vps34 inhibition triggers PD-L1 expression [118] while PI3Kδ induces the expression of PD-1 in CD8+ cells [139].”
BackgroundInfluentialBenoit, A., Vogin, G., Duhem, C., Berchem, G., & Janji, B. (2023) · Cells · doi:10.3390/cells12131787 · Cited by 39
Self-citationBao, Y., Qiao, Y., Choi, J. E., Zhang, Y., Mannan, R., Cheng, C., He, T., Zheng, Y., Yu, J., Gondal, M. N., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2314416120 · Cited by 42
Regulation of autophagy fires up the cold tumor microenvironment to improve cancer immunotherapy
Jin, Z., Sun, X., Wang, Y., Zhou, C., Yang, H., & Zhou, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1018903 · Cited by 40
Song, M., Qian, C., Zhang, T., Tang, Y. R., Zhou, Y., Wei, Z., Wang, A., Zhong, C., Zhao, Y., & Lu, Y. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116735 · Cited by 42
Autophagy: A Key Player in Pancreatic Cancer Progression and a Potential Drug Target
Gillson, J., El-Aziz, Y. S. A., Leck, L. Y. W., Jansson, P. J., Pavlakis, N., Samra, J. S., Mittal, A., & Sahni, S. (2022) · Cancers · doi:10.3390/cancers14143528 · Cited by 42
Structure-Based Design of Stapled Peptides That Bind GABARAP and Inhibit Autophagy
Brown, H., Chung, M., Üffing, A., Batistatou, N., Tsang, T., Doskocil, S. D., Mao, W., Willbold, D., Bast, R. C., Lü, Z., et al. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c04699 · Cited by 41
Logghe, T., van Zwol, E., Immordino, B., den Cruys, K. V., Peeters, M., Giovannetti, E., & Bogers, J. (2024) · Cancers · doi:10.3390/cancers16030505 · Cited by 42
Szpakowska, M., D’Uonnolo, G., Luís, R., Bartolomé, A. A., Thelen, M., Legler, D. F., & Chevigné, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1133394 · Cited by 40
The impact of autophagy during the development and survival of glioblastoma
Simpson, J. E., & Gammoh, N. (2020) · Open Biology · doi:10.1098/rsob.200184 · Cited by 37
“Noman MZ et al. 2020 Inhibition of Vps34 reprograms cold into hot inflamed tumors and improves anti-PD-1/PD-L1 immunotherapy.”
BackgroundInfluentialStrategies involving STING pathway activation for cancer immunotherapy: Mechanism and agonists
Pan, X., Zhang, W., Guo, H., Wang, L., Wu, H., Ding, L., & Yang, B. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115596 · Cited by 37
The role of autophagy in pancreatic cancer progression
Wang, Y., Qin, C., Yang, G., Zhao, B., & Wang, W. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188592 · Cited by 35
Targeting VPS34 in autophagy: An update on pharmacological small-molecule compounds
Liu, Y., Yang, Q., Chen, S., Li, Z., & Fu, L. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115467 · Cited by 35
Qu, J., Wu, B., Chen, L., Wen, Z., Fang, L., Zheng, J., Shen, Q., Heng, J., Zhou, J., & Zhou, J. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03046-3 · Cited by 36
“Noman et al. showed that STAT1/IRF7 upregulates CCL5 and CXCL10 expression, leading to the enhanced efficacy of anti-PD-1/ PD-L1 therapy[46].”
BackgroundZhang, S., Wang, X., Cai, Q.-Q., Chen, C., Zhang, Z.-Y., Xu, Y., Yang, M., Jia, Q.-A., Wang, Y., & Wang, Z.-M. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01137-1 · Cited by 36
Guo, W., Du, K., Luo, S., & Hu, D. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.861959 · Cited by 39
“The combination of anti-PD-1/ PD-L1 blockade and Vps34 inhibition promotes the mass production of pro-inflammatory cytokines and chemokines CCL5, CXCL10 and IFN-g, as well as the accumulation of CD4, CD8 T and NK cells, DCs and M1 macrophages, thus enhancing the efficacy of treatment (Figure 3) (91).”
BackgroundThe tumour-promoting role of protein homeostasis: Implications for cancer immunotherapy
Liang, R., Tan, H., Jin, H., Wang, J., Tang, Z., & Lu, X. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216354 · Cited by 35
Chu, C., Wang, Y.-W., Chen, Y.-L., Chen, H., Chuang, J.-J., Chang, H., Ho, C., Chang, C., Chow, N.-H., & Lee, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222010964 · Cited by 35
Unraveling the Intricacies of Autophagy and Mitophagy: Implications in Cancer Biology
Lee, S., Son, J.-Y., Lee, J., & Cheong, H. (2023) · Cells · doi:10.3390/cells12232742 · Cited by 35
“These anti-tumor immune cell infiltrations by Vps34 inhibition are caused by the upregulation of certain chemokines, CCL5 and CXCL10, thereby improving ICI therapeutic efficacy in melanoma and colorectal cancer mouse models [161].”
Background
Metadata
- Authors
- Noman, M. Z., Parpal, S., Van Moer, K., Xiao, M., Yu, Y., Arakelian, T., Viklund, J., De Milito, A., Hasmim, M., Andersson, M., Amaravadi, R. K., Martinsson, J., Berchem, G., & Janji, B.
- Affiliations
- Luxembourg Institute of Health (LU)
- Karolinska Institutet (SE)
- Tumor Immunotherapy and Microenvironment Group, Department of Oncology, Luxembourg Institute of Health (LIH), Luxembourg City, Luxembourg.
- Sprint Bioscience (Sweden) (SE)
- Sprint Bioscience, Stockholm, Sweden.
- Abramson Cancer Center (US)
- Centre Hospitalier de Luxembourg (LU)
- Corresponding author
- Berchem, Guy
- Janji, Bassam
- ORCID
- Venue
- Science Advances
- Published
- 2020-05
- Volume
- 6
- Issue
- 18
- Pages
- eaax7881-eaax7881
- ISSN
- 2375-2548 (ISSN-L)
- PMC
- PMC7190323
- OpenAlex
- W3021675475
- Cited by
- 255
- References
- 40
- Citations by year
- 2026: 24 · 2025: 25 · 2024: 51 · 2023: 46 · 2022: 55 · 2021: 39 · 2020: 15
- FWCI
- 14.53
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- Science Advances (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Luxembourg National Research Fund (C18/BM/12670304/COMBATIC)
- FNRS Televie (7.4664.15; 7.6503.16; 7.4606.18)
- Fondation Cancer, Luxembourg (FC/2016/01 and FC/2018/06)
- Kriibskrank Kanner Foundation Luxembourg (2016-08-15)
- Janssen Cilag Pharma
- Action LIONS Vaincre le Cancer, Luxembourg
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Keywords
- tumor immune microenvironment, PD-1/PD-L1 blockade, melanoma, colorectal cancer, T cell infiltration, RANTES, CXCL10, interferon-gamma, STAT1, IRF7, inflammatory chemokines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.